The popularity of copyright’s blockbuster initially fueled a boom for pharma, but recent changes present a murky outlook for investors. Generic competitors are eating into revenue, and ongoing litigation add https://estellextov457100.blogs-service.com/72288822/the-blue-pill-and-the-pharmaceutical-industry-a-precarious-investment